{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wen RM"],"funding":["NIH, DoD","NCRR NIH HHS","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["e180282"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11645153"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["134(24)"],"pubmed_abstract":["Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor-based immunotherapies have improved survival for many malignancies; however, they have failed to prolong survival for prostate cancer. Siglecs (sialic acid-binding immunoglobulin-like lectins) are expressed on immune cells and regulate their function. Siglec-7 and Siglec-9 contribute to immune evasion in cancer by interacting with sialic acid-containing glycoprotein ligands on cancer cells. However, the role of Siglec-7/9 receptors and their ligands in prostate cancer remains poorly understood. Here, we find that Siglec-7 and Siglec-9 are associated with poor prognosis in patients with prostate cancer and are highly expressed in myeloid cells, including macrophages, in prostate "],"journal":["The Journal of clinical investigation"],"pubmed_title":["Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer."],"pmcid":["PMC11645153"],"funding_grant_id":["F32 CA250324","S10 RR025518","W81XWH2110195,1F32CA250324-01,PF-20-143-01-LIB,R01CA227942,NIH K99 GM147304,U01CA226051,S10RR025518-01,S10RR027431-01","P30 CA014051","U01 CA226051","K99 GM147304","R01 CA227942","S10 RR027431"],"pubmed_authors":["Brooks JD","Garcia Marques FJ","Pitteri SJ","Fan Z","Engleman EG","Totten SM","Bertozzi CR","Wen RM","Fong L","Lyu A","Stark JC","Riley NM","Zhang X","Bermudez A","Marti GEW","Nolley R","Zhao H"],"additional_accession":[]},"is_claimable":false,"name":"Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer.","description":"Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor-based immunotherapies have improved survival for many malignancies; however, they have failed to prolong survival for prostate cancer. Siglecs (sialic acid-binding immunoglobulin-like lectins) are expressed on immune cells and regulate their function. Siglec-7 and Siglec-9 contribute to immune evasion in cancer by interacting with sialic acid-containing glycoprotein ligands on cancer cells. However, the role of Siglec-7/9 receptors and their ligands in prostate cancer remains poorly understood. Here, we find that Siglec-7 and Siglec-9 are associated with poor prognosis in patients with prostate cancer and are highly expressed in myeloid cells, including macrophages, in prostate ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-02T10:45:57.252Z","creation":"2025-04-04T01:54:59.075Z"},"accession":"S-EPMC11645153","cross_references":{"pubmed":["39436703"],"doi":["10.1172/JCI180282"]}}